Edesa Biotech Reports Increased Losses and R&D Spending in Q2 Fiscal 2026

Edesa Biotech, Inc. reported a significant increase in its financial losses for the second quarter of fiscal 2026, with a net loss of $4.2 million, or $0.49 per share, compared to a net loss of $1.6 million, or $0.30 per share, for the same period in the previous year. For the six months ended March 31, 2026, the company recorded a net loss of $6.5 million, up from $3.2 million in the prior year. Total operating expenses rose to $4.3 million for the three months ended March 31, 2026, compared to $1.6 million in the same quarter of 2025, driven primarily by increased research and development (R&D) costs associated with the company's clinical programs.

The company's R&D expenses surged to $2.8 million for the three months ended March 31, 2026, up from $0.5 million in the prior year, largely due to preparations for a planned Phase 2 clinical study of its EB06 drug candidate for vitiligo. General and administrative expenses also increased to $1.5 million from $1.2 million, reflecting higher salaries and professional fees. Edesa's total assets decreased to $12.4 million as of March 31, 2026, down from $13.5 million at the end of the previous fiscal year, while cash and cash equivalents fell to $10.0 million from $10.8 million.

In terms of strategic developments, Edesa Biotech has been actively pursuing funding to support its clinical programs. The company raised approximately $3.3 million through the issuance of common shares under its At The Market (ATM) offering agreement during the first half of fiscal 2026. Additionally, Edesa entered into a multi-year contribution agreement with the Canadian government’s Strategic Response Fund, which committed up to C$23 million in partially repayable funding for the development of its EB05 drug candidate. The company recorded grant income of $0.1 million for both the three and six months ended March 31, 2026, related to this agreement.

Operationally, Edesa Biotech has made progress in its clinical pipeline, particularly with its EB06 and paridiprubart drug candidates. The company has received regulatory approval from Health Canada to conduct a Phase 2 study of EB06 and is in discussions with the U.S. FDA for the same study. Paridiprubart has shown promising results in a truncated Phase 3 clinical study for Acute Respiratory Distress Syndrome (ARDS), demonstrating statistically significant improvements in survival and recovery rates. The company is also exploring additional uses for paridiprubart in chronic diseases.

Looking ahead, Edesa Biotech anticipates continued operating losses as it advances its clinical programs and seeks regulatory approvals. The company plans to pursue additional financing through equity sales, government grants, and potential collaborations to support its operations. Edesa's management has indicated that while it has sufficient cash to fund operations in the near term, it will need to secure further funding to sustain its development efforts through the end of fiscal 2026.